Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Olgun Elicin & Mahmut Ozsahin. (2016) Current Role of Dacomitinib in Head and Neck Cancer. Expert Opinion on Investigational Drugs 25:6, pages 735-742.
Read now
Read now
Chieh-Chien Lee, Hui-Yi Shiao, Wen-Chieh Wang & Hsing-Pang Hsieh. (2014) Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs 23:10, pages 1333-1348.
Read now
Read now
Robert Roskoski$suffix/text()$suffix/text(). (2013) The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opinion on Drug Discovery 8:9, pages 1165-1179.
Read now
Read now
Articles from other publishers (29)
Ibrahim A. Darwish & Hany W. Darwish. (2023) Development of novel green and high-throughput microwell spectrophotometric assay for one-step determination of dacomitinib, a recently approved potent drug for first-line treatment of metastatic non-small cell lung cancer. Sustainable Chemistry and Pharmacy 36, pages 101287.
Crossref
Crossref
Zhen-Xi Niu, Ya-Tao Wang, Nan Lu, Jin-Feng Sun, Peng Nie & Piet Herdewijn. (2023) Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry 261, pages 115868.
Crossref
Crossref
Rudradip Das, Gayatri Tambe & Amit Shard. (2023) Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents. Results in Chemistry 5, pages 100950.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
205
411
.
Amandeep Thakur, Chetna Faujdar, Ram Sharma, Sachin Sharma, Basant Malik, Kunal Nepali & Jing Ping Liou. (2022) Glioblastoma: Current Status, Emerging Targets, and Recent Advances. Journal of Medicinal Chemistry 65:13, pages 8596-8685.
Crossref
Crossref
Mudasir Nabi Peerzada, Ernest Hamel, Ruoli Bai, Claudiu T. Supuran & Amir Azam. (2021) Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacology & Therapeutics 225, pages 107860.
Crossref
Crossref
Ao Lu, Yidan Shi, Yijuan Liu, Jiahao Lin, Huarong Zhang, Yating Guo, Lisheng Li, Zeman Lin, Junling Wu, Daihan Ji & Chengdang Wang. (2021) Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma. Lung Cancer 158, pages 29-39.
Crossref
Crossref
Miguel Angel Galván Morales, Raúl Barrera Rodríguez, Julio Raúl Santiago Cruz & Luis M. Teran. (2020) Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules 25:23, pages 5686.
Crossref
Crossref
László Petri, Attila Egyed, Dávid Bajusz, Tímea Imre, Anasztázia Hetényi, Tamás Martinek, Péter Ábrányi-Balogh & György M. Keserű. (2020) An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases. European Journal of Medicinal Chemistry 207, pages 112836.
Crossref
Crossref
Yuan Liang, Tiehua Zhang & Jie Zhang. (2020) Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy. Pharmacological Research 161, pages 105164.
Crossref
Crossref
Omid Tavassoly, Takashi Sato & Iman Tavassoly. (2020) Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. Molecular Pharmacology 98:1, pages 13-22.
Crossref
Crossref
Yutaro Yamamoto, Tetsuya Saita, Yuta Yamamoto, Rintaro Sogawa, Sakiko Kimura, Yutaka Narisawa, Shinya Kimura & Masashi Shin. (2019) Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration. Acta Histochemica 121:8, pages 151439.
Crossref
Crossref
Mohamed W. Attwa, Adnan A. Kadi & Ali S. Abdelhameed. (2018)
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS:
in vitro
phase I metabolic investigation
. RSC Advances 8:68, pages 38733-38744.
Crossref
Crossref
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Ando, Motoi Ohba & Tohru Ohmori. (2018) Receptor Tyrosine Kinase-Targeted Cancer Therapy. International Journal of Molecular Sciences 19:11, pages 3491.
Crossref
Crossref
Paola Magnaghi, Barbara Salom, Liviana Cozzi, Nadia Amboldi, Dario Ballinari, Elena Tamborini, Fabio Gasparri, Alessia Montagnoli, Laura Raddrizzani, Alessio Somaschini, Roberta Bosotti, Christian Orrenius, Fabio Bozzi, Silvana Pilotti, Arturo Galvani, Josh Sommer, Silvia Stacchiotti & Antonella Isacchi. (2018) Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury. Molecular Cancer Therapeutics 17:3, pages 603-613.
Crossref
Crossref
Lei Chen, Jing Lu, Tao Huang & Yu-Dong Cai. (2017) A computational method for the identification of candidate drugs for non-small cell lung cancer. PLOS ONE 12:8, pages e0183411.
Crossref
Crossref
M. Raymond V. Finlay & Richard A. Ward. 2018. Cancer II. Cancer II
39
39
.
Jeff B. Smaill, Andrea J. Gonzales, Julie A. Spicer, Helen Lee, Jessica E. Reed, Karen Sexton, Irene W. Althaus, Tong Zhu, Shannon L. Black, Adrian Blaser, William A. Denny, Paul A. Ellis, Stephen Fakhoury, Patricia J. Harvey, Ken Hook, Florence O. J. McCarthy, Brian D. Palmer, Freddy Rivault, Kevin Schlosser, Teresa Ellis, Andrew M. Thompson, Erin Trachet, R. Thomas Winters, Haile Tecle & Alexander Bridges. (2016)
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-
d
]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
. Journal of Medicinal Chemistry 59:17, pages 8103-8124.
Crossref
Crossref
Nayoung Kim, Ahye Cho, Hideo Watanabe, Yoon-La Choi, Meraj Aziz, Michelle Kassner, Je-Gun Joung, Angela Kyung-Joo Park, Joshua M. Francis, Joon Seol Bae, Soo-min Ahn, Kyoung-Mee Kim, Joon Oh Park, Woong-Yang Park, Myung-Ju Ahn, Keunchil Park, Jaehyung Koo, Hongwei Holly Yin & Jeonghee Cho. (2016)
Integrated genomic approaches identify upregulation of
SCRN1
as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
. Oncotarget 7:12, pages 13797-13809.
Crossref
Crossref
Jessica E. Reed & Jeff B. Smaill. 2016. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1
207
233
.
Jing Shi & Jun Zhu. (2015) Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China. Clinical Drug Investigation 36:1, pages 77-86.
Crossref
Crossref
Yuliana Yosaatmadja, Shevan Silva, James M. Dickson, Adam V. Patterson, Jeff B. Smaill, Jack U. Flanagan, Mark J. McKeage & Christopher J. Squire. (2015) Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology 192:3, pages 539-544.
Crossref
Crossref
Laura Montermini, Brian Meehan, Delphine Garnier, Wan Jin Lee, Tae Hoon Lee, Abhijit Guha, Khalid Al-Nedawi & Janusz Rak. (2015) Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and Impacts Their Phosphoprotein and DNA Content. Journal of Biological Chemistry 290:40, pages 24534-24546.
Crossref
Crossref
Wei Cao, Ying Liu, Ran Zhang, Bo Zhang, Teng Wang, Xianbing Zhu, Lin Mei, Hongbo Chen, Hongling Zhang, Pinghong Ming & Laiqiang Huang. (2015) Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Scientific Reports 5:1.
Crossref
Crossref
Keith L. Davis, Ravi K. Goyal, Stephen L. Able, Jacqueline Brown, Li Li & James A. Kaye. (2015) Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer 87:2, pages 176-185.
Crossref
Crossref
Sam Santhosh, Prasanna Kumar, Vedam Ramprasad & Amitabha Chaudhuri. (2015) Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. Future Oncology 11:2, pages 279-293.
Crossref
Crossref
A. Mortlock, K. Foote, J. Kettle & B. Aquila. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
David S Shames & Ignacio I Wistuba. (2013) The evolving genomic classification of lung cancer. The Journal of Pathology 232:2, pages 121-133.
Crossref
Crossref
Katsuyuki Kiura & Mitsune Tanimoto. (2013) Lung cancer and molecular targeted drugs. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 125:1, pages 57-66.
Crossref
Crossref